Market Overview

UPDATE: SunTrust Robinson Humphrey Reiterates on Hologic as Deterioration Story Gains Momentum

Related HOLX
Hologic Jumps On Goldman Sachs News; Icahn And Other Fund Managers Are Also Bullish
BTIG: Hologic To Gain From Higher 3D Mammogram Reimbursements

In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan reiterated a Reduce rating on Hologic (NASDAQ: HOLX), but lowered the price target from $17.00 to $15.00.

In the report, SunTrust Robinson Humphrey noted, “New guidance for FY14 reflects the reality of deteriorating end markets and only the beginning of significant margin pressure in the years ahead. Declining EBITDA and a two year delay in leverage target guidance are similarly of high concern. Hopes for a return to growth by FY15 look entirely unrealistic to us, and we lower our PT from $17 to $15 in order to reflect what we view as notably greater risk.”

Hologic closed on Monday at $22.90.

Latest Ratings for HOLX

DateFirmActionFromTo
Dec 2014Goldman SachsMaintainsBuy
Nov 2014JefferiesMaintainsBuy
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: Amit Hazan SunTrust Robinson HumphreyAnalyst Color Price Target Analyst Ratings

 

Related Articles (HOLX)

Around the Web, We're Loving...

Get Benzinga's Newsletters